BioCina and NovaCina team up to enhance biologics manufacturing capabilities

52
Image credit: BioCina

BioCina, a biologics Contract Development and Manufacturing Organisation (CDMO), has joined hands with NovaCina, a global fill-and-finish CDMO, to establish a strategic alliance aimed at offering integrated drug substance and drug product solutions for biologics developers.

This collaborative effort enables BioCina to extend its service portfolio by integrating high-quality fill-and-finish solutions provided by NovaCina, the former said in a press release.

The partnership facilitates the transformation of drug substances produced at BioCina’s cutting-edge facility in Adelaide, South Australia, into ready-to-use drug products at NovaCina’s advanced facility in Perth, Australia.

This union also marks a significant stride towards delivering comprehensive biopharmaceutical manufacturing solutions to clients worldwide.

In particular, BioCina specialises in delivering top-tier, cost-effective CDMO services, encompassing cell line development, process development, and cGMP drug substance manufacturing across microbial, pDNA, and mRNA modalities.

Through this strategic alliance, BioCina’s clientele stands to benefit from NovaCina’s extensive clinical and commercial fill-and-finish expertise, backed by a multitude of regulatory approvals, including those from the US Food and Drug Administration (FDA).

NovaCina offers a wide array of services ranging from development and manufacturing to packaging, labelling, and stability studies.

Mark W. Womack, CEO of BioCina and member of NovaCina’s Board of Directors, expressed his enthusiasm about the partnership, highlighting the fusion of BioCina’s globally recognized proficiency in clinical and commercial process development and drug substance manufacturing with NovaCina’s esteemed drug product services.

“This partnership promises to deliver unparalleled quality, adherence to the highest regulatory standards, and on-time delivery of client programs, setting a new benchmark in the market,” Womack noted.

Cyrus K. Mirsaidi, CEO of NovaCina, echoed Womack’s sentiments, expressing excitement about the collaboration.

“Together, we provide a seamless end-to-end offering. At NovaCina, we are delighted to bring our world-class quality and safety to this value-adding collaboration,” Mirsaidi concluded.